Fixed-dose combination of phentermine-topiramate for the treatment of obesity

Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13.

Abstract

The aim of this article is to focus on the fixed-dose combination of phentermine and topiramate, a new antiobesity drug recently approved by the US FDA. The mechanisms of weight loss for each drug in monotherapy is described, followed by the rationale for its use as a combination therapy and a comprehensive review of recently published clinical trials that assessed its efficacy and safety.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents / therapeutic use*
  • Appetite Depressants / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Fructose / analogs & derivatives*
  • Fructose / therapeutic use
  • Humans
  • Obesity / drug therapy*
  • Phentermine / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Topiramate
  • Treatment Outcome

Substances

  • Anti-Obesity Agents
  • Appetite Depressants
  • Drug Combinations
  • Topiramate
  • Fructose
  • Phentermine